RNAi-based drug design: considerations and future directions
Open accessThe DOI matches its Crossref record; 264 of the 264 references it cites were found in a registry or an index.
Abstract
More than 25 years after its discovery, the post-transcriptional gene regulation mechanism termed RNAi is now transforming pharmaceutical development, proved by the recent FDA approval of multiple small interfering RNA (siRNA) drugs that target the liver. Synthetic siRNAs that trigger RNAi have the potential to specifically silence virtually any therapeutic target with unprecedented potency and durability. Bringing this innovative class of medicines to patients, however, has been riddled with substantial challenges, with delivery issues at the forefront. Several classes of siRNA drug are under clinical evaluation, but their utility in treating extrahepatic diseases remains limited, demanding continued innovation. In this Review, we discuss principal considerations and future directions in the design of therapeutic siRNAs, with a particular emphasis on chemistry, the application of informatics, delivery strategies and the importance of careful target selection, which together influence therapeutic success. Since the groundbreaking discovery of RNAi more than 25 years ago, several small interfering RNA (siRNA)-based therapies that target the liver have gained approval. This Review discusses principal considerations in siRNA-based drug development, focusing on the medicinal chemistry of siRNA design, the application of informatics, delivery platforms and future directions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Gene regulation by long non-coding RNAs and its biological functions
Statello, L., Guo, C.-J., Chen, L.-L., & Huarte, M. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00315-9 · Cited by 4,991
Role for a bidentate ribonuclease in the initiation step of RNA interference
Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001) · Nature · doi:10.1038/35053110 · Cited by 4,892
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 1×
“These oligonucleotides, termed antagomirs (or anti-miRs) 78 , bind to the loaded guide strand in RISC, thus blocking its target recognition and silencing activity (Fig.”
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Ischemia and reperfusion—from mechanism to translation
Eltzschig, H. K., & Eckle, T. (2011) · Nature Medicine · doi:10.1038/nm.2507 · Cited by 3,382
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005
Asymmetry in the Assembly of the RNAi Enzyme Complex
Schwarz, D. S., Hutvágner, G., Du, T., Xu, Z., Aronin, N., & Zamore, P. D. (2003) · Cell · doi:10.1016/s0092-8674(03)00759-1 · Cited by 2,922
Brook, J. D., McCurrach, M. E., Harley, H. G., Buckler, A. J., Church, D., Aburatani, H., Hunter, K., Stanton, V. P., Thirion, J.-P., Hudson, T., et al. (1992) · Cell · doi:10.1016/0092-8674(92)90154-5 · Cited by 2,777
Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80620-0 · Cited by 2,676
Functional siRNAs and miRNAs exhibit strand bias
Khvorova, A., Reynolds, A., & Jayasena, S. D. (2003) · Cell · doi:10.1016/s0092-8674(03)00801-8 · Cited by 2,645 · cited 1×
“For example, thermodynamic bias 56,89 — also called strand asymmetry — is a principal component of efficacy for unmodified siRNAs, but in modified siRNAs asymmetry is usually chemically defined and thus contributes less.”
Self-citationExosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383 · cited 1×
“…CRISPR–Cas gene-editing systems and siRNA) to extrahepatic tissues, including lung, spleen and solid tumours, with improved selectivity to certain cell types 106–110 ; this will potentially open new avenues for the functional delivery of siRNAs to these tissues using the established LNP platforms.”
Expression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370 · cited 1×
“The realization that siRNAs faced serious hurdles, such as immunogenicity 230–234 and off-targeting effects 69,235,236 , quickly led to doubt in the technology, as pharmaceutical companies cut funding and abandoned their RNAi platforms 237,238 .”
Long non-coding RNAs: definitions, functions, challenges and recommendations
Mattick, J. S., Amaral, P. P., Carninci, P., Carpenter, S., Chang, H. Y., Chen, L.-L., Chen, R., Dean, C., Dinger, M. E., Fitzgerald, K. A., et al. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00566-8 · Cited by 2,356
A polymorphic DNA marker genetically linked to Huntington's disease
Gusella, J. F., Wexler, N. S., Conneally, P. M., Naylor, S. L., Anderson, M. A., Tanzi, R. E., Watkins, P. C., Ottina, K., Wallace, M. R., Sakaguchi, A. Y., et al. (1983) · Nature · doi:10.1038/306234a0 · Cited by 2,347
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Expansion of the eukaryotic proteome by alternative splicing
Nilsen, T. W., & Graveley, B. R. (2010) · Nature · doi:10.1038/nature08909 · Cited by 2,197
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677 · cited 1×
“37).”
The role of non-coding RNAs in oncology
Slack, F. J., & Chinnaiyan, A. M. (2019) · Cell · doi:10.1016/j.cell.2019.10.017 · Cited by 1,619
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443 · cited 1×
“Every aspect of the diverse preclinical and clinical evaluations cannot be covered here, and much of the mechanistic details of RNAi biology and RNAi therapeutics have been reviewed elsewhere 15 .”
Hardiman, O., Al-Chalabi, A., Chio, A., Corr, E. M., Logroscino, G., Robberecht, W., Shaw, P. J., Simmons, Z., & van den Berg, L. H. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.71 · Cited by 1,414
Activation of the interferon system by short-interfering RNAs
Sledz, C. A., Holko, M., de Veer, M. J., Silverman, R. H., & Williams, B. R. G. (2003) · Nature Cell Biology · doi:10.1038/ncb1038 · Cited by 1,400
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Can Animal Models of Disease Reliably Inform Human Studies?
van der Worp, H. B., Howells, D. W., Sena, E. S., Porritt, M. J., Rewell, S., O'Collins, V., & Macleod, M. R. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000245 · Cited by 1,354 · cited 1×
“Additionally, the relevance of an animal model — that is, whether it accurately resembles the human disease characteristics 181–183 — is essential, particularly for inflammatory disorders and cancers where the exact cause of the disease might be unknown.”
Understanding alternative splicing: towards a cellular code
Matlin, A. J., Clark, F., & Smith, C. W. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1645 · Cited by 1,305
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,232
The promises and pitfalls of RNA-interference-based therapeutics
Castanotto, D., & Rossi, J. J. (2009) · Nature · doi:10.1038/nature07758 · Cited by 1,221
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
Self-citationInterfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
Transfer learning enables predictions in network biology
Theodoris, C. V., Xiao, L., Chopra, A., Chaffin, M. D., Al Sayed, Z. R., Hill, M. C., Mantineo, H., Brydon, E. M., Zeng, Z., Liu, X. S., et al. (2023) · Nature · doi:10.1038/s41586-023-06139-9 · Cited by 1,193 · cited 1×
“Advances in genetics, multi-omics and artificial intelligence for target prediction, based on large numbers of complex human datasets, have shown strong promise 165–168 .”
Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery
Lee, H., Lytton-Jean, A. K. R., Chen, Y., Love, K. T., Park, A. I., Karagiannis, E. D., Sehgal, A., Querbes, W., Zurenko, C. S., Jayaraman, M., et al. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.73 · Cited by 1,169
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
Overcoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139
RNA interference targeting Fas protects mice from fulminant hepatitis
Song, E., Lee, S.-K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., & Lieberman, J. (2003) · Nature Medicine · doi:10.1038/nm828 · Cited by 1,110
Unlocking the potential of the human genome with RNA interference
Hannon, G. J., & Rossi, J. J. (2004) · Nature · doi:10.1038/nature02870 · Cited by 1,064
RNA interference in adult mice
McCaffrey, A. P., Meuse, L., Pham, T.-T. T., Conklin, D. S., Hannon, G. J., & Kay, M. A. (2002) · Nature · doi:10.1038/418038a · Cited by 1,059
Caplen, N. J., Parrish, S., Imani, F., Fire, A., & Morgan, R. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171251798 · Cited by 1,043
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Antisense technologies: Improvement through novel chemical modifications
Kurreck, J. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03555.x · Cited by 1,006
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity
Jackson, A. L., Burchard, J., Schelter, J., Chau, B. N., Cleary, M., Lim, L., & Linsley, P. S. (2006) · RNA · doi:10.1261/rna.25706 · Cited by 956
3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets
Birmingham, A., Anderson, E. M., Reynolds, A., Ilsley-Tyree, D., Leake, D., Fedorov, Y., Baskerville, S., Maksimova, E., Robinson, K., Karpilow, J., et al. (2006) · Nature Methods · doi:10.1038/nmeth854 · Cited by 920
Self-citationsiRNAs: applications in functional genomics and potential as therapeutics
Dorsett, Y., & Tuschl, T. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1345 · Cited by 909
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy
Kim, D.-H., Behlke, M. A., Rose, S. D., Chang, M.-S., Choi, S., & Rossi, J. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1051 · Cited by 884
Functional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831 · cited 1×
“Therapeutic modulation of myostatin may be beneficial for treating muscular dystrophies 178–180 .”
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818 · cited 1×
“…by the recent positive clinical results of zilebesiran in treating hypertension 241,242 , as well as the approval of inclisiran (2020) in the European Union (EU) and (2021) in the USA for the treatment of hypercholesterolaemia — a major cause of atherosclerotic cardiovascular disease 243,244 .”
Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing
Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J. M., Lim, L., Karpilow, J., Nichols, K., et al. (2006) · RNA · doi:10.1261/rna.30706 · Cited by 789
Self-citationRNA-Binding Protein Dnd1 Inhibits MicroRNA Access to Target mRNA
Kedde, M., Strasser, M. J., Boldajipour, B., Vrielink, J. A. F. O., Slanchev, K., le Sage, C., Nagel, R., Voorhoeve, P. M., van Duijse, J., Ørom, U. A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.034 · Cited by 732
DNA repair mechanisms in dividing and non-dividing cells
Iyama, T., & Wilson, D. M. (2013) · DNA Repair · doi:10.1016/j.dnarep.2013.04.015 · Cited by 697
The Crystal Structure of Human Argonaute2
Schirle, N. T., & MacRae, I. J. (2012) · Science · doi:10.1126/science.1221551 · Cited by 696
Dilliard, S. A., & Siegwart, D. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-022-00529-7 · Cited by 671
The cGAS–STING pathway and cancer
Samson, N., & Ablasser, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00468-w · Cited by 668
Structural basis for 5′-nucleotide base-specific recognition of guide RNA by human AGO2
Frank, F., Sonenberg, N., & Nagar, B. (2010) · Nature · doi:10.1038/nature09039 · Cited by 666
Mouse Models of Human Disease: An Evolutionary Perspective
Perlman, R. L. (2016) · Evolution, Medicine, and Public Health · doi:10.1093/emph/eow014 · Cited by 647
Frank-Kamenetsky, M., Grefhorst, A., Anderson, N. N., Racie, T. S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 642
Patisiran: First Global Approval
Hoy, S. M. (2018) · Drugs · doi:10.1007/s40265-018-0983-6 · Cited by 614
Scacheri, P. C., Rozenblatt-Rosen, O., Caplen, N. J., Wolfsberg, T. G., Umayam, L., Lee, J. C., Hughes, C. M., Shanmugam, K. S., Bhattacharjee, A., Meyerson, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308698100 · Cited by 613
Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy
Chen, X., Firulyova, M., Manis, M., Herz, J., Smirnov, I., Aladyeva, E., Wang, C., Bao, X., Finn, M. B., Hu, H., et al. (2023) · Nature · doi:10.1038/s41586-023-05788-0 · Cited by 609
DNA nanotechnology from the test tube to the cell
Chen, Y.-J., Groves, B., Muscat, R. A., & Seelig, G. (2015) · Nature Nanotechnology · doi:10.1038/nnano.2015.195 · Cited by 594
Dassie, J. P., Liu, X.-Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., & Giangrande, P. H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1560 · Cited by 589
In vivo activity of nuclease-resistant siRNAs
LAYZER, J. M., MCCAFFREY, A. P., TANNER, A. K., HUANG, Z., KAY, M. A., & SULLENGER, B. A. (2004) · RNA · doi:10.1261/rna.5239604 · Cited by 580
RNA splicing dysregulation and the hallmarks of cancer
Bradley, R. K., & Anczuków, O. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00541-7 · Cited by 579 · cited 2×
“This process may result in regulatory RNA and protein isoforms that differ in biological function and pathological roles, which have been suggested in certain cancers and neurodegenerative disorders 192–196 .”
T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice
Kumar, P., Ban, H.-S., Kim, S.-S., Wu, H., Pearson, T., Greiner, D. L., Laouar, A., Yao, J., Haridas, V., Habiro, K., et al. (2008) · Cell · doi:10.1016/j.cell.2008.06.034 · Cited by 570
Structural basis for microRNA targeting
Schirle, N. T., Sheu-Gruttadauria, J., & MacRae, I. J. (2014) · Science · doi:10.1126/science.1258040 · Cited by 562
Kopp, J. B., Anders, H.-J., Susztak, K., Podestà, M. A., Remuzzi, G., Hildebrandt, F., & Romagnani, P. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0196-7 · Cited by 562
Wang, X., Liu, S., Sun, Y., Yu, X., Lee, S. M., Cheng, Q., Wei, T., Gong, J., Robinson, J., Zhang, D., et al. (2023) · Nature Protocols · doi:10.1038/s41596-022-00755-x · Cited by 549
Structure of the guide-strand-containing argonaute silencing complex
Wang, Y., Sheng, G., Juranek, S., Tuschl, T., & Patel, D. J. (2008) · Nature · doi:10.1038/nature07315 · Cited by 543
Karikó, K., Bhuyan, P., Capodici, J., & Weissman, D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.6545 · Cited by 449
Allerson, C. R., Sioufi, N., Jarres, R., Prakash, T. P., Naik, N., Berdeja, A., Wanders, L., Griffey, R. H., Swayze, E. E., & Bhat, B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049167j · Cited by 448
Aptamer mediated siRNA delivery
Chu, T. C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl388 · Cited by 446
Woodrow, K. A., Cu, Y., Booth, C. J., Saucier-Sawyer, J. K., Wood, M. J., & Mark Saltzman, W. (2009) · Nature Materials · doi:10.1038/nmat2444 · Cited by 438
Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque
Li, B.-J., Tang, Q., Cheng, D., Qin, C., Xie, F. Y., Wei, Q., Xu, J., Liu, Y., Zheng, B.-J., Woodle, M. C., et al. (2005) · Nature Medicine · doi:10.1038/nm1280 · Cited by 433
Self-citationDelivery of oligonucleotides to the liver with GalNAc: From research to registered therapeutic drug.
Debacker, A. J., Voutila, J., Catley, M., Blakey, D., & Habib, N. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.015 · Cited by 424
Potent effect of target structure on microRNA function
Long, D., Lee, R., Williams, P., Chan, C. Y., Ambros, V., & Ding, Y. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1226 · Cited by 422
An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection
Palliser, D., Chowdhury, D., Wang, Q.-Y., Lee, S. J., Bronson, R. T., Knipe, D. M., & Lieberman, J. (2006) · Nature · doi:10.1038/nature04263 · Cited by 410
Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation
Zheng, D., Giljohann, D. A., Chen, D. L., Massich, M. D., Wang, X.-Q., Iordanov, H., Mirkin, C. A., & Paller, A. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118425109 · Cited by 409
Allele-specific silencing of dominant disease genes
Miller, V. M., Xia, H., Marrs, G. L., Gouvion, C. M., Lee, G., Davidson, B. L., & Paulson, H. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1231012100 · Cited by 400
Design of a genome-wide siRNA library using an artificial neural network
Huesken, D., Lange, J., Mickanin, C., Weiler, J., Asselbergs, F., Warner, J., Meloon, B., Engel, S., Rosenberg, A., Cohen, D., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1118 · Cited by 386
Lamb, Y. N. (2021) · Drugs · doi:10.1007/s40265-021-01473-6 · Cited by 359
Activation of the mammalian immune system by siRNAs
Marques, J. T., & Williams, B. R. G. (2005) · Nature Biotechnology · doi:10.1038/nbt1161 · Cited by 358
Manoharan, M. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00138-4 · Cited by 348
Biological roles of adenine methylation in RNA
Boulias, K., & Greer, E. L. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00534-0 · Cited by 342
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37515 · Cited by 336
Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
Foster, D. J., Brown, C. R., Shaikh, S., Trapp, C., Schlegel, M. K., Qian, K., Sehgal, A., Rajeev, K. G., Jadhav, V., Manoharan, M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.021 · Cited by 325
An accurate and interpretable model for siRNA efficacy prediction
Vert, J.-P., Foveau, N., Lajaunie, C., & Vandenbrouck, Y. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-520 · Cited by 323
Development of Lipidoid–siRNA Formulations for Systemic Delivery to the Liver
Akinc, A., Goldberg, M., Qin, J., Dorkin, J. R., Gamba-Vitalo, C., Maier, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Manoharan, M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.36 · Cited by 323
Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 Therapy
Zhou, J., Li, H., Li, S., Zaia, J., & Rossi, J. J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.92 · Cited by 301
Method of the year: long-read sequencing
Marx, V. (2023) · Nature Methods · doi:10.1038/s41592-022-01730-w · Cited by 295
DNA nanostructures coordinate gene silencing in mature plants
Zhang, H., Demirer, G. S., Zhang, H., Ye, T., Goh, N. S., Aditham, A. J., Cunningham, F. J., Fan, C., & Landry, M. P. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818290116 · Cited by 290
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension
Desai, A. S., Webb, D. J., Taubel, J., Casey, S., Cheng, Y., Robbie, G. J., Foster, D., Huang, S. A., Rhyee, S., Sweetser, M. T., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2208391 · Cited by 287
Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
Brown, C. R., Gupta, S., Qin, J., Racie, T., He, G., Lentini, S., Malone, R., Yu, M., Matsuda, S., Shulga-Morskaya, S., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa670 · Cited by 285
Koller, E., Vincent, T. M., Chappell, A., De, S., Manoharan, M., & Bennett, C. F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr089 · Cited by 281
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
Janas, M. M., Schlegel, M. K., Harbison, C. E., Yilmaz, V. O., Jiang, Y., Parmar, R., Zlatev, I., Castoreno, A., Xu, H., Shulga-Morskaya, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02989-4 · Cited by 279 · cited 2×
“Although siRNAs have been shown to cause toxicity in vivo by seed-based off-targeting 73 , most do not 49,72 .”
Yu, D., Pendergraff, H., Liu, J., Kordasiewicz, H. B., Cleveland, D. W., Swayze, E. E., Lima, W. F., Crooke, S. T., Prakash, T. P., & Corey, D. R. (2012) · Cell · doi:10.1016/j.cell.2012.08.002 · Cited by 278
Nair, J. K., Attarwala, H., Sehgal, A., Wang, Q., Aluri, K., Zhang, X., Gao, M., Liu, J., Indrakanti, R., Schofield, S., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx818 · Cited by 278
Designing siRNA That Distinguish between Genes That Differ by a Single Nucleotide
Schwarz, D. S., Ding, H., Kennington, L., Moore, J. T., Schelter, J., Burchard, J., Linsley, P. S., Aronin, N., Xu, Z., & Zamore, P. D. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020140 · Cited by 271
The response of mammalian cells to double-stranded RNA
Gantier, M. P., & Williams, B. R. G. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.06.016 · Cited by 265
Neff, C. P., Zhou, J., Remling, L., Kuruvilla, J., Zhang, J., Li, H., Smith, D. D., Swiderski, P., Rossi, J. J., & Akkina, R. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001581 · Cited by 259
Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates
Brown, K. M., Nair, J. K., Janas, M. M., Anglero-Rodriguez, Y. I., Dang, L. T. H., Peng, H., Theile, C. S., Castellanos-Rizaldos, E., Brown, C., Foster, D., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01334-x · Cited by 258 · cited 2×
“Indeed, different scaffolds can generate distinct cell-type uptake profiles 51,52,99,145 .”
Nuclear Retention of mRNA in Mammalian Tissues
Bahar Halpern, K., Caspi, I., Lemze, D., Levy, M., Landen, S., Elinav, E., Ulitsky, I., & Itzkovitz, S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.11.036 · Cited by 258
Single-Stranded siRNAs Activate RNAi in Animals
Lima, W. F., Prakash, T. P., Murray, H. M., Kinberger, G. A., Li, W., Chappell, A. E., Li, C. S., Murray, S. F., Gaus, H., Seth, P. P., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.014 · Cited by 256
Nonhuman primate models of human viral infections
Estes, J. D., Wong, S. W., & Brenchley, J. M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0005-7 · Cited by 255
Adam, R., Spier, I., Zhao, B., Kloth, M., Marquez, J., Hinrichsen, I., Kirfel, J., Tafazzoli, A., Horpaopan, S., Uhlhaas, S., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.06.015 · Cited by 251
Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury
Hamar, P., Song, E., Kökény, G., Chen, A., Ouyang, N., & Lieberman, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406421101 · Cited by 250
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication
Theruvath, J., Menard, M., Smith, B. A. H., Linde, M. H., Coles, G. L., Dalton, G. N., Wu, W., Kiru, L., Delaidelli, A., Sotillo, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01625-x · Cited by 249
Lee, J.-H., Canny, M. D., De Erkenez, A., Krilleke, D., Ng, Y.-S., Shima, D. T., Pardi, A., & Jucker, F. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509069102 · Cited by 242
MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer’s disease
Balusu, S., Horré, K., Thrupp, N., Craessaerts, K., Snellinx, A., Serneels, L., T’Syen, D., Chrysidou, I., Arranz, A. M., Sierksma, A., et al. (2023) · Science · doi:10.1126/science.abp9556 · Cited by 230
Alterman, J. F., Godinho, B. M. D. C., Hassler, M. R., Ferguson, C. M., Echeverria, D., Sapp, E., Haraszti, R. A., Coles, A. H., Conroy, F., Miller, R., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0205-0 · Cited by 227 · cited 5×
“Local administration of optimized siRNAs into the CNS, eye, lung and skin has shown robust efficacy 49,52,99,143,144 .”
InfluentialSelf-citationWheeler, L. A., Trifonova, R., Vrbanac, V., Basar, E., McKernan, S., Xu, Z., Seung, E., Deruaz, M., Dudek, T., Einarsson, J. I., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45876 · Cited by 227
CD8+ T cells induce interferon-responsive oligodendrocytes and microglia in white matter aging
Kaya, T., Mattugini, N., Liu, L., Ji, H., Cantuti-Castelvetri, L., Wu, J., Schifferer, M., Groh, J., Martini, R., Besson-Girard, S., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01183-6 · Cited by 224
A protocol for designing siRNAs with high functionality and specificity
Birmingham, A., Anderson, E., Sullivan, K., Reynolds, A., Boese, Q., Leake, D., Karpilow, J., & Khvorova, A. (2007) · Nature Protocols · doi:10.1038/nprot.2007.278 · Cited by 222
Self-citationDevelopment of antibody-siRNA conjugate targeted to cardiac and skeletal muscles
Sugo, T., Terada, M., Oikawa, T., Miyata, K., Nishimura, S., Kenjo, E., Ogasawara-Shimizu, M., Makita, Y., Imaichi, S., Murata, S., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.036 · Cited by 221
From target discovery to clinical drug development with human genetics
Trajanoska, K., Bhérer, C., Taliun, D., Zhou, S., Richards, J. B., & Mooser, V. (2023) · Nature · doi:10.1038/s41586-023-06388-8 · Cited by 220
van de Water, F. M., Boerman, O. C., Wouterse, A. C., Peters, J. G. P., Russel, F. G. M., & Masereeuw, R. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009555 · Cited by 217
Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate
Zimmermann, T. S., Karsten, V., Chan, A., Chiesa, J., Boyce, M., Bettencourt, B. R., Hutabarat, R., Nochur, S., Vaishnaw, A., & Gollob, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.019 · Cited by 216
RNAi modulation of placental sFLT1 for the treatment of preeclampsia
Turanov, A. A., Lo, A., Hassler, M. R., Makris, A., Ashar-Patel, A., Alterman, J. F., Coles, A. H., Haraszti, R. A., Roux, L., Godinho, B. M. D. C., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4297 · Cited by 213
Self-citationDelivery of siRNA and other macromolecules into skin and cells using a peptide enhancer
Hsu, T., & Mitragotri, S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016152108 · Cited by 209
Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo
Biscans, A., Coles, A., Haraszti, R., Echeverria, D., Hassler, M., Osborn, M., & Khvorova, A. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1239 · Cited by 205
Self-citationKnocking down Disease with siRNAs
Dykxhoorn, D. M., & Lieberman, J. (2006) · Cell · doi:10.1016/j.cell.2006.07.007 · Cited by 197
Unique Gene‐Silencing and Structural Properties of 2′‐Fluoro‐Modified siRNAs
Manoharan, M., Akinc, A., Pandey, R. K., Qin, J., Hadwiger, P., John, M., Mills, K., Charisse, K., Maier, M. A., Nechev, L., et al. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201006519 · Cited by 193
Alternative splicing in neurodegenerative disease and the promise of RNA therapies
Nikom, D., & Zheng, S. (2023) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00717-6 · Cited by 190
Targeted delivery of antisense oligonucleotides to pancreatic β-cells
Ämmälä, C., Drury, W. J., Knerr, L., Ahlstedt, I., Stillemark-Billton, P., Wennberg-Huldt, C., Andersson, E.-M., Valeur, E., Jansson-Löfmark, R., Janzén, D., et al. (2018) · Science Advances · doi:10.1126/sciadv.aat3386 · Cited by 188
Fomivirsen – a phosphorothioate oligonucleotide for the treatment of CMV retinitis
de Smet, M. D., Meenken, C., & van den Horn, G. J. (1999) · Ocular Immunology and Inflammation · doi:10.1076/ocii.7.3.189.4007 · Cited by 187
Glomerulonephritis: immunopathogenesis and immunotherapy
Anders, H.-J., Kitching, A. R., Leung, N., & Romagnani, P. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00816-y · Cited by 186
A high confidence, manually validated human blood plasma protein reference set
Schenk, S., Schoenhals, G. J., de Souza, G., & Mann, M. (2008) · BMC Medical Genomics · doi:10.1186/1755-8794-1-41 · Cited by 181
Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo
Hassler, M. R., Turanov, A. A., Alterman, J. F., Haraszti, R. A., Coles, A. H., Osborn, M. F., Echeverria, D., Nikan, M., Salomon, W. E., Roux, L., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky037 · Cited by 181 · cited 1×
“Indeed, full stabilization of the scaffold by incorporating modifications at every nucleotide position and several terminal backbone modifications profoundly improves siRNA accumulation and potency in tissues 26 .”
Self-citationNew Approaches to Chronic Hepatitis B
Dusheiko, G., Agarwal, K., & Maini, M. K. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2211764 · Cited by 180
Comparison of approaches for rational siRNA design leading to a new efficient and transparent method
Matveeva, O., Nechipurenko, Y., Rossi, L., Moore, B., Saetrom, P., Ogurtsov, A. Y., Atkins, J. F., & Shabalina, S. A. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm088 · Cited by 179
Targeted tissue delivery of RNA therapeutics using antibody–oligonucleotide conjugates (AOCs)
Malecová, B., Burke, R. S., Cochran, M., Hood, M. D., Johns, R. E., Kovach, P., Doppalapudi, V. R., Erdogan, G., Arias, J. D., Darimont, B. D., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad415 · Cited by 177
siRNA target site secondary structure predictions using local stable substructures
Heale, B. S. E. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni026 · Cited by 176
Chen, P. Y., Weinmann, L., Gaidatzis, D., Pei, Y., Zavolan, M., Tuschl, T., & Meister, G. (2008) · RNA · doi:10.1261/rna.789808 · Cited by 176
The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress
Dua, K., Wadhwa, R., Singhvi, G., Rapalli, V., Shukla, S. D., Shastri, M. D., Gupta, G., Satija, S., Mehta, M., Khurana, N., et al. (2019) · Drug Development Research · doi:10.1002/ddr.21571 · Cited by 175
Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide
Tran, H., Moazami, M. P., Yang, H., McKenna-Yasek, D., Douthwright, C. L., Pinto, C., Metterville, J., Shin, M., Sanil, N., Dooley, C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01557-6 · Cited by 174
Delivery of RNA Therapeutics: The Great Endosomal Escape!
Dowdy, S. F., Setten, R. L., Cui, X.-S., & Jadhav, S. G. (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2022.0004 · Cited by 174
Computational models with thermodynamic and composition features improve siRNA design
Shabalina, S. A., Spiridonov, A. N., & Ogurtsov, A. Y. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-65 · Cited by 170
Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates
Kota, J., Handy, C. R., Haidet, A. M., Montgomery, C. L., Eagle, A., Rodino-Klapac, L. R., Tucker, D., Shilling, C. J., Therlfall, W. R., Walker, C. M., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000112 · Cited by 166
MSH3 modifies somatic instability and disease severity in Huntington’s and myotonic dystrophy type 1
Flower, M., Lomeikaite, V., Ciosi, M., Cumming, S., Morales, F., Lo, K., Hensman Moss, D., Jones, L., Holmans, P., Monckton, D. G., et al. (2019) · Brain · doi:10.1093/brain/awz115 · Cited by 165
Ichihara, M., Murakumo, Y., Masuda, A., Matsuura, T., Asai, N., Jijiwa, M., Ishida, M., Shinmi, J., Yatsuya, H., Qiao, S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm699 · Cited by 162
Target accessibility dictates the potency of human RISC
Brown, K. M., Chu, C., & Rana, T. M. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb931 · Cited by 149
Osborn, M. F., Coles, A. H., Biscans, A., Haraszti, R. A., Roux, L., Davis, S., Ly, S., Echeverria, D., Hassler, M. R., Godinho, B. M. D. C., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1232 · Cited by 146
Self-citationExperimental validation of the importance of seed complement frequency to siRNA specificity
Anderson, E. M., Birmingham, A., Baskerville, S., Reynolds, A., Maksimova, E., Leake, D., Fedorov, Y., Karpilow, J., & Khvorova, A. (2008) · RNA · doi:10.1261/rna.704708 · Cited by 144
Self-citationDennis, C. (2002) · Nature · doi:10.1038/418122a · Cited by 143
Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction
Lee, S.-J. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148372 · Cited by 143
Parmar, R., Willoughby, J. L. S., Liu, J., Foster, D. J., Brigham, B., Theile, C. S., Charisse, K., Akinc, A., Guidry, E., Pei, Y., et al. (2016) · ChemBioChem · doi:10.1002/cbic.201600130 · Cited by 141
Aptamer-Based Targeted Delivery of Functional Nucleic Acids
Xie, S., Sun, W., Fu, T., Liu, X., Chen, P., Qiu, L., Qu, F., & Tan, W. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c00841 · Cited by 137
Ray, T. A., Cochran, K., Kozlowski, C., Wang, J., Alexander, G. C., Cady, M. A., Spencer, W. J., Ruzycki, P. A., Clark, B. S., Laeremans, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17009-7 · Cited by 133
Sano, M., Sierant, M., Miyagishi, M., Nakanishi, M., Takagi, Y., & Sutou, S. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn584 · Cited by 132
Gulhati, P., Schalck, A. P., Jiang, S., Shang, X., Wu, C., Hou, P., Ruiz, S. H., Soto, L. M. S., Parra, E. R., Ying, H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00500-z · Cited by 128
Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations
Mandal, A., Kumbhojkar, N., Reilly, C. B., Dharamdasani, V., Ukidve, A., Ingber, D. E., & Mitragotri, S. (2020) · Science Advances · doi:10.1126/sciadv.abb6049 · Cited by 126
5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo
Haraszti, R. A., Roux, L., Coles, A. H., Turanov, A. A., Alterman, J. F., Echeverria, D., Godinho, B. M. D. C., Aronin, N., & Khvorova, A. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx507 · Cited by 124
Self-citationAlternative splicing of SYK regulates mitosis and cell survival
Prinos, P., Garneau, D., Lucier, J., Gendron, D., Couture, S., Boivin, M., Brosseau, J., Lapointe, E., Thibault, P., Durand, M., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2040 · Cited by 122
Retinitis pigmentosa and allied conditions today: a paradigm of translational research
Ayuso, C., & Millán, J. M. (2010) · Genome Medicine · doi:10.1186/gm155 · Cited by 121
Chang, C. I., Yoo, J. W., Hong, S. W., Lee, S. E., Kang, H. S., Sun, X., Rogoff, H. A., Ban, C., Kim, S., Li, C. J., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.298 · Cited by 118
mRNA turnover rate limits siRNA and microRNA efficacy
Larsson, E., Sander, C., & Marks, D. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.89 · Cited by 118
RNA-binding protein isoforms ZAP-S and ZAP-L have distinct antiviral and immune resolution functions
Schwerk, J., Soveg, F. W., Ryan, A. P., Thomas, K. R., Hatfield, L. D., Ozarkar, S., Forero, A., Kell, A. M., Roby, J. A., So, L., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0527-6 · Cited by 118
La Rocca, G., Olejniczak, S. H., González, A. J., Briskin, D., Vidigal, J. A., Spraggon, L., DeMatteo, R. G., Radler, M. R., Lindsten, T., Ventura, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424217112 · Cited by 117
Schlegel, M. K., Janas, M. M., Jiang, Y., Barry, J. D., Davis, W. P., Agarwal, S., Berman, D., Brown, C. R., Castoreno, A. B., LeBlanc, S., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac539 · Cited by 110
Judge, D. P., Kristen, A. V., Grogan, M., Maurer, M. S., Falk, R. H., Hanna, M., Gillmore, J., Garg, P., Vaishnaw, A. K., Harrop, J., et al. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06919-4 · Cited by 107
A systematic review of PCSK9 inhibitors alirocumab and evolocumab
McDonagh, M., Peterson, K., Holzhammer, B., & Fazio, S. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.6.641 · Cited by 103
Reversal of siRNA-mediated gene silencing in vivo
Zlatev, I., Castoreno, A. B., Brown, C. R., Qin, J., Waldron, S., Schlegel, M. K., Degaonkar, R., Shulga‐Morskaya, S., Xu, H., Gupta, S., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4136 · Cited by 103
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
Richardson, P. G., Trudel, S., Popat, R., Mateos, M.-V., Vangsted, A. J., Ramasamy, K., Martinez-Lopez, J., Quach, H., Orlowski, R. Z., Arnao, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303194 · Cited by 102
Cui, J., Qin, L., Zhang, J., Abrahimi, P., Li, H., Li, G., Tietjen, G. T., Tellides, G., Pober, J. S., & Mark Saltzman, W. (2017) · Nature Communications · doi:10.1038/s41467-017-00297-x · Cited by 101
Topical delivery of siRNA into skin using ionic liquids
Dharamdasani, V., Mandal, A., Qi, Q. M., Suzuki, I., Bentley, M. V. L. B., & Mitragotri, S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.038 · Cited by 100
Prakash, T. P., Lima, W. F., Murray, H. M., Li, W., Kinberger, G. A., Chappell, A. E., Gaus, H., Seth, P. P., Bhat, B., Crooke, S. T., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv162 · Cited by 98
Thielmann, M., Corteville, D., Szabo, G., Swaminathan, M., Lamy, A., Lehner, L. J., Brown, C. D., Noiseux, N., Atta, M. G., Squiers, E. C., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.053029 · Cited by 97
Long‐lasting RNAi activity in mammalian neurons
Omi, K., Tokunaga, K., & Hohjoh, H. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00017-1 · Cited by 97
Nuclear retention of mRNAs – quality control, gene regulation and human disease
Wegener, M., & Müller-McNicoll, M. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.11.001 · Cited by 96
Jahns, H., Roos, M., Imig, J., Baumann, F., Wang, Y., Gilmour, R., & Hall, J. (2015) · Nature Communications · doi:10.1038/ncomms7317 · Cited by 94
Snead, N. M., Wu, X., Li, A., Cui, Q., Sakurai, K., Burnett, J., & Rossi, J. J. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt200 · Cited by 90
Elkayam, E., Parmar, R., Brown, C. R., Willoughby, J. L., Theile, C. S., Manoharan, M., & Joshua-Tor, L. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1171 · Cited by 89
Takahashi, M., Koi, M., Balaguer, F., Boland, C. R., & Goel, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.198804 · Cited by 87
The regulatory impact of RNA-binding proteins on microRNA targeting
Kim, S., Kim, S., Chang, H. R., Kim, D., Park, J., Son, N., Park, J., Yoon, M., Chae, G., Kim, Y.-K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25078-5 · Cited by 87
Stojic, L., Niemczyk, M., Orjalo, A., Ito, Y., Ruijter, A. E. M., Uribe-Lewis, S., Joseph, N., Weston, S., Menon, S., Odom, D. T., et al. (2016) · Nature Communications · doi:10.1038/ncomms10406 · Cited by 84
Engineering DNA nanostructures for siRNA delivery in plants
Zhang, H., Zhang, H., Demirer, G. S., Grandío, E. G., Fan, C., & Landry, M. P. (2020) · Nature Protocols · doi:10.1038/s41596-020-0370-0 · Cited by 84
RNA interference therapeutics in organ transplantation: The dawn of a new era
Brüggenwirth, I. M. A., & Martins, P. N. A. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15689 · Cited by 82
Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa
Meng, D., Ragi, S. D., & Tsang, S. H. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.08.012 · Cited by 82
Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
Janas, M. M., Zlatev, I., Liu, J., Jiang, Y., Barros, S. A., Sutherland, J. E., Davis, W. P., Liu, J., Brown, C. R., Liu, X., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz140 · Cited by 79
Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown
Zhang, Y., Xie, X., Yeganeh, P. N., Lee, D.-J., Valle‐García, D., Meza‐Sosa, K. F., Junqueira, C., Su, J., Luo, H. R., Hide, W., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022830118 · Cited by 79
Development and Characterization of Gene Silencing DNA Cages
Fakhoury, J. J., McLaughlin, C. K., Edwardson, T. G. W., Conway, J. W., & Sleiman, H. F. (2013) · Biomacromolecules · doi:10.1021/bm401532n · Cited by 75
Biscans, A., Caiazzi, J., McHugh, N., Hariharan, V., Muhuri, M., & Khvorova, A. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.023 · Cited by 74
Self-citationAmbike, S. S., Cheng, C., Feuerherd, M., Velkov, S., Baldassi, D., Afridi, S. Q., Porras-Gonzalez, D., Wei, X. C., Hagen, P., Kneidinger, N., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1248 · Cited by 74
Wheeler, L. A., Vrbanac, V. D., Trifonova, R. T., Brehm, M. A., Gilboa-Geffen, A., Tanno, S., Greiner, D. L., Luster, A. D., Tager, A. M., & Lieberman, J. (2013) · Molecular Therapy · doi:10.1038/mt.2013.77 · Cited by 73
Biscans, A., Caiazzi, J., Davis, S. M., McHugh, N., Sousa, J., & Khvorova, A. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa595 · Cited by 72
Self-citation
Cited by
Small and long non-coding RNAs: Past, present, and future
Chen, L.-L., & Kim, V. N. (2024) · Cell · doi:10.1016/j.cell.2024.10.024 · Cited by 425
Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259
Metadata
- Authors
- Tang, Q., & Khvorova, A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2024-04-03
- Volume
- 23
- Issue
- 5
- Pages
- 341-364
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W4393869156
- Cited by
- 282
- References
- 264
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.